Literature DB >> 7788964

Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice.

K Tanaka1, M Tanaka, S Igarashi, O Onodera, T Miyatake, S Tsuji.   

Abstract

Passive transfer of serum IgG or mononuclear cells from peripheral blood of a patient with paraneoplastic cerebellar degeneration (PCD) to rodents was carried out in order to examine the role of anti-Purkinje cell antibody (anti-Yo antibody) present in serum and cerebrospinal fluid of PCD patients. After a single injection of IgG into mouse brain, it was taken up by Purkinje cells and remained there for more than 36 h without Purkinje cell loss. Injection of PCD IgG together with complement or lipopolysaccharide-activated human macrophages or rat mononuclear cells into rat ventricles did not cause Purkinje cell loss. We also studied passive transfer of the PCD patient's lymphocytes to mice with severe combined immunodeficiency (SCID). We constructed a recombinant Yo fusion protein that has the leucine-zipper protein (Yo protein), the common epitope for anti-Yo antibody for immunizing mice, and that resulted in production of significant amounts of anti-Yo antibody. Spleen cells from these Yo protein immunized mice were injected intravenously or intracerebrally into naive mice that subsequently showed no neurological symptoms or loss of Purkinje cells. We conclude that the anti-Yo antibody, either in combination with or without complement or activated mononuclear cells, cannot be the sole cause of Purkinje cell loss.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788964     DOI: 10.1016/0303-8467(95)00006-6

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  23 in total

Review 1.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

2.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  Autoimmune epilepsies.

Authors:  Christian G Bien; Jan Bauer
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

5.  'Moonlighting' surface antigens: a paradigm for autoantibody pathogenicity in neurology?

Authors:  Sarosh R Irani
Journal:  Brain       Date:  2016-02       Impact factor: 13.501

6.  Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures.

Authors:  John E Greenlee; Susan A Clawson; Kenneth E Hill; Blair L Wood; Ikuo Tsunoda; Noel G Carlson
Journal:  J Neuropathol Exp Neurol       Date:  2010-10       Impact factor: 3.685

7.  Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.

Authors:  J Honnorat
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

8.  A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization.

Authors:  Sven Jarius; Klaus P Wandinger; Sigrun Horn; Heike Heuer; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2010-03-12       Impact factor: 8.322

Review 9.  Encephalitis and epilepsy.

Authors:  Jan Bauer; Christian G Bien
Journal:  Semin Immunopathol       Date:  2009-09-11       Impact factor: 9.623

10.  [Pathophysiology of antibody-associated diseases of the central nervous system].

Authors:  C G Bien; J Bauer
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.